Skip to main content
menu Toggle navigation
Certificate/SDS search Buy from VWR

Investor Relations

Setting science in motion to create a better world

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve.

Investor Day
Bioproduction Overview - Woman and young girl smiling BIOPRODUCTION & AVANTOR FLUID HANDLING OVERVIEW

Biopharma spotlight

We have deep ties to the scientific and pharma industries and are supporting key breakthroughs and life-changing treatments for patients. Biopharma accounts for more than 50% of our revenue. Our portfolio of nearly 6 million different products is used in virtually every stage of the most important research, development and production work, such as monoclonal antibodies, cell and gene therapy, vaccines.

2021 Financial Summary1

~$7.4B

Revenue

11.3%

Organic revenue
growth

~$1.5B

Adj. EBITDA

~190bps

Adj. EBITDA margin expansion

$1.41

Adj. EPS

57.7%

Adj. EPS
growth

$920M

Free Cash Flow

~100%

Free Cash Flow
conversion2


1. See "Reconciliations of Non-GAAP measures" in our annual report on Form 10-K and our 4Q 2021 quarterly earnings materials for a discussion of non-GAAP measures.
2. Free Cash Flow conversion is defined as Free Cash Flow / Adj. Net Income. Included in 4Q 2021 earnings materials.

Latest News

All News

Latest Events

All Events & Presentations

Featured Video

home video

We Set Science in Motion to Create a Better World